Share the post "Beryl Drugs announced Financial Results Q1 2024-25"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company’s sales declined by -22.9 % over the year, substantial increase in net sales/revenue by 109.98 %.
- Income over the Year and quarter: There has been decline in other income over the past year which is -41.54 %, Marginal decrease of -83.69% in other income during this quarter.
- Profit over the Year and quarter: Challenges in sustaining profitability for Beryl Drugs Ltd.. Profit dropped by -30.57 % Year to Year, Beryl Drugs Ltd.’s profitability dropped by -206.05 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -30.48 % Year to Year. EPS decreased by -207.35 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 8.105 Cr | Rs. 2.976 Cr | Rs. 6.249 Cr | + 109.98 % | -22.9 % |
| Expenses | Rs. 7.04 Cr | Rs. 3.19 Cr | Rs. 5.3 Cr | + 66.14 % | -24.72 % |
| Operating Profit | Rs. 1.07 Cr | Rs. -0.21 Cr | Rs. 0.95 Cr | + 552.38 % | -11.21 % |
| OPM % | 13.2 % | -7.06 % | 15.2 % | + 22.26 % | + 2 % |
| Other Income | Rs. 0.065 Cr | Rs. 0.233 Cr | Rs. 0.038 Cr | -83.69 % | -41.54 % |
| Interest | Rs. 0.12 Cr | Rs. 0.13 Cr | Rs. 0.21 Cr | + 61.54 % | + 75 % |
| Depreciation | Rs. 0.28 Cr | Rs. 0.32 Cr | Rs. 0.28 Cr | -12.5 % | + 0 % |
| Profit before tax | Rs. 0.74 Cr | Rs. -0.43 Cr | Rs. 0.5 Cr | + 216.28 % | -32.43 % |
| Tax % | 27.4 % | -17.97 % | 25.81 % | + 43.78 % | -1.59 % |
| Net Profit | Rs. 0.53 Cr | Rs. -0.35 Cr | Rs. 0.37 Cr | + 205.71 % | -30.19 % |
| EPS in Rs | Rs. 1.05 | Rs. -0.68 | Rs. 0.73 | + 207.35 % | -30.48 % |
Today, we’re looking at Beryl Drugs Ltd.’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -22.9 %. However, it did see a marginal increase of 109.98 % from the previous quarter. Expenses ticked up slightly by 66.14 % quarter-on-quarter, aligning with the annual decline of -24.72 %. Operating profit, while down -11.21 % compared to last year, faced a quarter-on-quarter increase of 552.38 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2 %, but an expansion of 22.26 % sequentially. Other income fell by -83.69 % compared to the last quarter, despite an annual decline of -41.54 %. Interest expenses surged remarkably by 61.54 % from the previous quarter, yet the year-over-year increase remains at a moderate 75 %. Depreciation costs fell by -12.5 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 0 %. Profit before tax declined annually by -32.43 % but saw an increase from the preceding quarter by 216.28 %.
Tax expenses as a percentage of profits decreased slightly by -1.59 % compared to last year, with a more notable quarter-on-quarter increase of 43.78 %. Net profit fell by -30.19 % year-on-year but experienced a 205.71 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -30.48 % but a quarterly rise of 207.35 %. In summary, Beryl Drugs Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 8.105 Cr | Rs. 2.976 Cr | Rs. 6.249 Cr | + 109.98 % | -22.9 % |
| Expenses | Rs. 7.04 Cr | Rs. 3.19 Cr | Rs. 5.3 Cr | + 66.14 % | -24.72 % |
| Operating Profit | Rs. 1.07 Cr | Rs. -0.21 Cr | Rs. 0.95 Cr | + 552.38 % | -11.21 % |
| Net Profit | Rs. 0.53 Cr | Rs. -0.35 Cr | Rs. 0.37 Cr | + 205.71 % | -30.19 % |
| EPS in Rs | Rs. 1.05 | Rs. -0.68 | Rs. 0.73 | + 207.35 % | -30.48 % |
In reviewing Beryl Drugs Ltd.’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -22.9 % year-on-year, however, there was a minor increase of 109.98 % from the previous quarter. Expenses decreased by -24.72 % compared to the previous year, with a 66.14 % increase quarter-on-quarter. Operating Profit dropped by -11.21 % annually, and saw a 552.38 % increase from the last quarter.
Net Profit showed yearly decrease of -30.19 %, and experienced a 205.71 % increase from the previous quarter. Earnings Per Share (EPS) fell by -30.48 % annually, however rose by 207.35 % compared to the last quarter. In essence, while Beryl Drugs Ltd. faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
[my_shortcode1 values=”Beryl Drugs “]
